When was OncoStem founded?

OncoStem was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is OncoStem located?

OncoStem is headquartered in Bengaluru, India. It is registered at Anand Towers, Municipal No.4 Rajaram Mohan Roy Road, Sampangiramanaga, r, Bangalore, Bangalore, Karnataka, India, 560027.

Who is the current CEO of OncoStem?

Manjiri Bakre of OncoStem. They have also founded 1 company.

Which legal entities is OncoStem associated with?

OncoStem is associated with Oncostem Diagnostics Private Limited.

How many employees does OncoStem have?

As of Aug 31, 2025, the latest employee count at OncoStem is 18.

Is OncoStem a funded company?

OncoStem is a funded company, having raised a total of $9M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2011.

When was the latest funding round of OncoStem?

OncoStem's latest funding was a $***** Series A round on Sep 06, 2017, with participation from 2 investors.

What is the annual revenue of OncoStem?

Annual revenue of OncoStem is between ₹10 Cr and ₹50 Cr as on Mar 31, 2025

Where does OncoStem rank among its competitors?

OncoStem ranks 70th amongst 359 active competitors, of which 122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Adela, which secured $5M in Apr, 2026.

Who are the top competitors of OncoStem?

OncoStem's top competitors include MedGenome, Caris Life Sciences and Geneoscopy. Among them, Adela secured the most recent funding round in April, 2026.

OncoStem - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of prognostic tests for the detection of cancer. The company's flagship product is CanAssist-Breast, which uses a proprietary Artificial Intelligence-based statistical model to identify the patient's risk of breast cancer recurrence. Also, it provides additional information about the tumor, based on which the cancer treatment can be customized.

Website: www.oncostem.com/
Registered Address: Anand Towers, Municipal No.4 Rajaram Mohan Roy Road, Sampangiramanaga, r, Bangalore, Bangalore, Karnataka, India, 560027

Key Metrics

Founded Year

2011

Location

Bengaluru, India

Stage

Series A

Total Funding

$9M in 2 rounds

Latest Funding Round

Series A, Sep 06, 2017, $*****

Investors

Artiman & 2 more

Ranked

70^th among 359 active competitors

Annual Revenue

₹10 - ₹50 Cr as on Mar 31, 2025

Employee Count

18 as on Aug 31, 2025

Similar Companies

MedGenome & 506 more

View OncoStem's full profile

OncoStem is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Oncostem Diagnostics Private Limited CIN: U85110KA2011PTC057624 , India, Active	Mar 15, 2011	₹10 - ₹50 Cr (As on Mar 31, 2025)	19 (As on May 01, 2026)

OncoStem has raised a total funding of $9M over 2 rounds. Its first funding round was on 2011. Its latest funding round was a Series A round on Sep 06, 2017 for $*****. 2 investors participated in its latest round. OncoStem has 3 institutional investors.

Here is the list of recent funding rounds of OncoStem:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 06, 2017	1321539	Series A	7207189	5636898	4741702	7996058
2011	5274	Seed	4061	5397	Artiman	6836

Access funding benchmarks and valuations. Sign up today!

View details of OncoStem's funding rounds and investors

The founders of OncoStem is Manjiri Bakre. Manjiri Bakre is the CEO of OncoStem.

Here are the details of OncoStem's key team members:

Manjiri Bakre: Founder & CEO of OncoStem. They serve on the board of 1 company.
Contact Info: 1 phone number

OncoStem's Board of Directors

OncoStem's board has 4 active members. Manjiri Bakre and Satyanarayana Thallam are part of team and Prem Kumar and Vasanth Shantha Prashanth are independent board members.

Here is the list of OncoStem's board of directors:

Name	Type	Representing	Status	Duration
Manjiri Bakre	Team	-	Current	15y 1m
psghrbm	Team	-	Current	8y 9m
airgofz	Independent board member	-	Past	1y 3m
jlmofex	Independent board member	-	Past	5y 7m
agmectv	Independent board member	-	Past	5y 2m

View details of OncoStem's Founder profiles and Board Members

OncoStem's employee count trend

OncoStem has 18 employees as of Aug 25. The total employee count is 5.0% lower than what it was in Aug 24. Here is OncoStem's employee count trend over the years:

Uncover OncoStem's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoStem include MedGenome, Caris Life Sciences and Geneoscopy. Here is the list of Top 10 competitors of OncoStem, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	71/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
3rd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Orbimed & 10 others	66/100
5th	Adela 2021, San Francisco (United States), Series A	Developer of a platform for detection of cancer	$139M	F-Prime Capital, LabCorp & 5 others	62/100
6th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
7th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
8th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	61/100
9th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Jennison, Perceptive Advisors & 17 others	61/100
10th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
70th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100